Literature DB >> 21723456

Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus.

Michael R Pranzatelli1, Patricia R Slev, Elizabeth D Tate, Anna L Travelstead, Jerry A Colliver, Suja Anne Joseph.   

Abstract

Oligoclonal bands in cerebrospinal fluid reflect local B-cell responses associated with various neuroinflammatory disorders. In opsoclonus-myoclonus syndrome, cerebrospinal fluid B-cell expansion was demonstrated, but no studies of oligoclonal bands are available. In a prospective case-control study of 132 children (103 with opsoclonus-myoclonus, 29 neurologic control subjects), cerebrospinal fluid oligoclonal bands, measured by isoelectric focusing with immunofixation, were observed in 35% with opsoclonus-myoclonus and none of the control subjects, with the highest frequency in severe cases (56%). In oligoclonal band-positive patients, the mean band number was 5 ± 3 S.D. (range, 2-10) and the total severity score was significantly higher than in band-negative patients, whereas the frequency of CD19(+) B cells, opsoclonus-myoclonus duration, neuroblastoma detection, and relapse history did not differ. The cerebrospinal fluid immunoglobulin G synthesis rate, immunoglobulin index, and Q albumin were normal. In 17 untreated children receiving adrenocorticotropic hormone, intravenous immunoglobulins, and rituximab, the number of oligoclonal band-positive decreased by 75%, and the mean band count fell by 80%. Oligoclonal band detection adds useful information to neuroimmunologic "staging" in opsoclonus-myoclonus. However, flow cytometry provides a more sensitive measure of B-cell infiltration. Cerebrospinal fluid oligoclonal bands warrant monitoring in long-term follow-up studies of disease-modifying drugs for opsoclonus-myoclonus.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723456     DOI: 10.1016/j.pediatrneurol.2011.02.012

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  4 in total

1.  Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.

Authors:  M R Pranzatelli; E D Tate; N R McGee; A L Travelstead; S J Verhulst; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

Review 2.  The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder.

Authors:  Nancy Ratner; Garrett M Brodeur; Russell C Dale; Nina F Schor
Journal:  Ann Neurol       Date:  2016-04-30       Impact factor: 10.422

3.  Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

4.  BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee; Anna L Travelstead; Jerry A Colliver; Jayne M Ness; Richard M Ransohoff
Journal:  J Neuroinflammation       Date:  2013-01-16       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.